Healthcare Biz Recap: Teva FALLS, Edwards Lifesciences Gets FDA OK
Teva’s (NASDAQ:TEVA) shares fall, even as its copaxone multiple sclerosis drug performed well against a placebo in a Phase III trial, which evaluated its effectiveness under a new dosage regime of 40mg three times a week, as opposed to the typical 20mg per day schedule.
Edwards Lifesciences (NYSE:EW) gets the okay from an FDA advisory panel for expanded use of its Sapien artificial heart valve as an alternative to open heart surgery. The proposal that the benefits of the transcatheter heart valve for patients considered high-risk and capable of handling surgery would surpass the risks, won an 11 to 0 vote, although the panel was wary of the possibility of raised danger of stroke. A full FDA decision might come by October.
Shares of Osiris Therapeutics (NASDAQ:OSIR) take off, following the news that it‘s given the green light to market its stem cell therapy Prochymal in New Zealand for the treatment of graft-vs-host disease ((GvHD)) in children. The drug won approval in Canada last month, and marks the first therapy approved for GvHD, which occurs when immune cells in transplanted bone marrow attack the recipient’s body cells.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.